Benefit of doxycycline treatment on articular disability caused by dialysis related amyloidosis

Amyloid

Volumn 20, Issue 3, 2013, Pages 173-178

  Montagna, Giovanni ^a   Cazzulani, Benedetta ^a   Obici, Laura ^b   Uggetti, Carla ^c   Giorgetti, Sofia ^d   Porcari, Riccardo ^e   Ruggiero, Rubina ^a   Patrizia Mangione, P ^d,e   Brambilla, Moreno ^a   Lucchetti, Jacopo ^f   Guiso, Giovanna ^f   Gobbi, Marco ^f   Merlini, Giampaolo ^b,d   Salmona, Mario ^f   Stoppini, Monica ^d   Villa, Giuseppe ^a   Bellotti, Vittorio ^d,e  

^a IRCCS   (Italy)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^c SAN CARLO BORROMEO HOSPITAL   (Italy)

^d UNIVERSITY OF PAVIA   (Italy)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

^f MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

2 Microglobulin; Amyloid fibrils; Inhibition of fibrillogenesis; Long term dialysis; Tetracyclines

Indexed keywords

DOXYCYCLINE;

ADULT; AMYLOIDOSIS; ARTICLE; ARTICULAR IMPAIRMENT; CARPAL TUNNEL SYNDROME; CASE REPORT; CHRONIC KIDNEY FAILURE; DIALYSIS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ESOPHAGITIS; HEMODIALYSIS; HIP ARTHROPLASTY; HUMAN; LONG TERM CARE; MALE; PAIN; PRIORITY JOURNAL; TREATMENT DURATION;

EID: 84882962397     PISSN: 13506129     EISSN: 17442818     Source Type: Journal    
DOI: 10.3109/13506129.2013.803463     Document Type: Article

References (31)

1. Gejyo F, Yamada T, Odani S, Nakagawa Y, Arakawa M, Kunitomo T, Kataoka H, et al. A new form of amyloid protein associated with chronic hemodialysis was identified as beta 2-microglobulin. Biochem Biophys Res Commun 1985;129:701-6. (Pubitemid 15243930)
2. Giorgetti S, Stoppini M, Tennent GA, Relini A, Marchese L, Raimondi S, Monti M, et al. Lysine 58-cleaved beta2-microglobulin is not detectable by 2D electrophoresis in ex vivo amyloid fibrils of two patients affected by dialysis-related amyloidosis. Protein Sci 2007;16:343-9. (Pubitemid 46155784)
3. Giorgetti S, Raimondi S, Cassinelli S, Bucciantini M, Stefani M, Gregorini G, Albonico G, et al. beta2-microglobulin is potentially neurotoxic, but the blood brain barrier is likely to protect the brain from its toxicity. Nephrol Dial Transplant 2009;24:1176-81.
4. Danesh F, Ho LT. Dialysis-related amyloidosis: history and clinical manifestations. Semin Dial 2001;14:80-5. (Pubitemid 33720831)
5. Yamamoto S, Kazama JJ, Maruyama H, Nishi S, Narita I, Gejyo F. Patients undergoing dialysis therapy for 30 years or more survive with serious osteoarticular disorders. Clin Nephrol 2008;70: 496-502.
6. Bellotti V, Nuvolone M, Giorgetti S, Obici L, Palladini G, Russo P, Lavatelli F, et al. The workings of the amyloid diseases. Ann Med 2007;39:200-7. (Pubitemid 46676479)
7. De Lorenzi E, Giorgetti S, Grossi S, Merlini G, Caccialanza G, Bellotti V. Pharmaceutical strategies against amyloidosis: old and new drugs in targeting a "protein misfolding disease". Curr Med Chem 2004;11:1065-84. (Pubitemid 38425931)
8. Woods LA, Platt GW, Hellewell AL, Hewitt EW, Homans SW, Ashcroft AE, Radford SE. Ligand binding to distinct states diverts aggregateion of an amyloid-forming protein. Nat Chem Biol 2011; 28:730-9.
9. Giorgetti S, Raimondi S, Pagano K, Relini A, Bucciantini M, Corazza A, Fogolari F, et al. Effect of tetracyclines on the dynamics of formation and destructuration of beta2-microglobulin amyloid fibrils. J Biol Chem 2011;286:2121-31.
10. Merlini G, Ascari E, Amboldi N, Bellotti V, Arbustini E, Perfetti V, Ferrari M, et al. Interaction of the anthracycline 40-iodo-40-deoxydoxorubicin with amyloid fibrils: inhibition of amyloidogenesis. Proc Natl Acad Sci USA 1995;92:2959-63.
11. Tagliavini F, Forloni G, Colombo L, Rossi G, Girola L, Canciani B, Angeretti N, et al. Tetracycline affects abnormal properties of synthetic PrP peptides and PrP(Sc) in vitro. J Mol Biol 2000;300: 1309-22.
12. De Luigi A, Colombo L, Diomede L, Capobianco R, Mangieri M, Miccolo C, Limido L, et al. The efficacy of tetracyclines in peripheral and intracerebral prion infection. PLoS One 2008;3: e1888.
13. Cardoso I, Saraiva MJ. Doxycycline disrupts transthyretin amyloid: evidence from studies in a FAP transgenic mice model. FASEB J 2006;20:234-9. (Pubitemid 44933170)
14. Forloni G, Colombo L, Girola L, Tagliavini F, Salmona M. Antiamyloidogenic activity of tetracyclines: studies in vitro. FEBS Lett 2001;487:404-7. (Pubitemid 32121764)
15. Diomede L, Cassata G, Fiordaliso F, Salio M, Ami D, Natalello A, Doglia SM, et al. Tetracycline and its analogues protect Caenorhabditis elegans from b amyloid-induced toxicity by targeting oligomers. Neurobiol Dis 2010;40:424-31.
16. Aitken JF, Loomes KM, Konarkowska B, Cooper GJ. Suppression by polycyclic compounds of the conversion of human amylin into insoluble amyloid. Biochem J 2003;374:779-84. (Pubitemid 37163925)
17. Aitken JF, Loomes KM, Scott DW, Reddy S, Phillips AR, Prijic G, Fernando C, et al. Tetracycline treatment retards the onset and slows the progression of diabetes in human amylin/islet amyloid polypeptide transgenic mice. Diabetes 2010;59:161-71.
18. Malmo C, Vilasi S, Iannuzzi C, Tacchi S, Cametti C, Irace G, Sirangelo I. Tetracycline inhibits W7FW14F apomyoglobin fibril extension and keeps the amyloid protein in a pre-fibrillar, highly cytotoxic state. FASEB J 2006;20:346-67.
19. Loeb MB, Molloy DW, Smieja M, Standish T, Goldsmith CH, Mahony J, Smith S, et al. A randomized, controlled trial of doxycycline and rifampin for patients with Alzheimer's disease. J Am Geriatr Soc 2004;52:381-7. (Pubitemid 38339518)
20. Obici L, Cortese A, Lozza A, Lucchetti J, Gobbi M, Palladini G, Perlini S, et al. Doxycycline plus tauroursodeoxycholic acid for transthyretin amyloidosis: a phase II study. Amyloid 2012;19:34-6.
21. Colovic M, Caccia S. Liquid chromatographic determination of minocycline in brain-to-plasma distribution studies in the rat. J Chromatogr B Analyt Technol Biomed Life Sci 2003;791:337-43. (Pubitemid 36638766)
22. Montagna G, Raimondi S, Moro G, Uggetti C, Relini A, Magrini U, Esposito G, et al. Clinical, radiological, and biochemical features of a bilateral buttock amyloidoma emerging after 27 years of hemodialysis. Amyloid 2009;16:115-21.
23. Houin G, Brunner F, Nebout T, Cherfaoui M, Lagrue G, Tillement JP. The effects of chronic renal insufficiency on the pharmacokinetics of doxycycline in man. Br J Clin Pharmacol 1983;16:245-52. (Pubitemid 13043509)
24. Saivin S, Houin G. Clinical pharmacokinetics of doxycycline and minocycline. Clin Pharmacokinet 1988;15:355-66. (Pubitemid 19012674)
25. Webster G, Del Rosso JQ. Anti-inflammatory activity of tetracyclines. Dermatol Clin 2007;25:133-5. (Pubitemid 46566395)
26. Greenwald RA. The road forward: the scientific basis for tetracycline treatment of arthritic disorders. Pharmacol Res 2011; 64:610-3.
27. Bellotti V, Chiti F. Amyloidogenesis in its biological environment: challenging a fundamental issue in protein misfolding diseases. Curr Opin Struct Biol 2008;18:771-9.
28. Mourad G, Argilés A. Renal transplantation relieves the symptoms but does not reverse beta 2-microglobulin amyloidosis. J Am Soc Nephrol 1996;7:798-804.
29. Campistol JM. Dialysis-related amyloidosis after renal transplantation. Semin Dial 2001;14:99-102. (Pubitemid 33720835)
30. Gejyo F, Amano I, AndoT, Ishida M, Obayashi S, Ogawa H, Ono T, et al. Society of b2-Microglobulin Adsorption Therapy. Survey of the effects of a column for adsorption of b2-microglobulin in patients with dialysis-related amyloidosis in Japan. Ther Apher Dial 2013;17:40-7.
31. Liabeuf S, Lenglet A, Desjardins L, Neirynck N, Glorieux G, Lemke HD, Vanholder R, et al. European Uremic Toxin Work Group (EUTox). Plasma beta-2 microglobulin is associated with cardiovascular disease in uremic patients. Kidney Int 2012;12: 1297-303.